The path from the incretin effect in the 1960s to triple agonists in the 2020s is one of the fastest stories in pharmacology.
| Year | Milestone |
|---|---|
| 1960-70s | Incretin effect discovered: insulin response higher for oral glucose |
| 1980s | GLP-1 identified as the active hormone |
| 2005 | Exenatide (Byetta) — from Gila monster saliva, first GLP-1 drug |
| 2010 | Liraglutide (Victoza/Saxenda) — daily |
| 2017 | Semaglutide (Ozempic) — weekly |
| 2022 | Tirzepatide (Mounjaro) — dual GIP+GLP-1 |
| 2020s | Retatrutide — triple GIP+GLP-1+GCG |
Long half-lives (acylation — an 'anchor' to albumin) turned daily injections weekly; multi-agonism widened targets. Our class pages: mechanics (RU) · encyclopedia.
Exenatide — from a compound in Gila monster saliva.
An acylated side chain binds albumin — half-life ~165 h.